Skip to main content
SpringerLink
Log in

Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

This study compared the changes over time in the volume of prescriptions of COX-2 selective inhibitors between rural and urban Queensland to reveal any difference in the uptake of the prescribing of these new drugs between two geographically distinct areas.

Methods

This study used data from an administrative claims database. Dispensing data were obtained for celecoxib and rofecoxib in two areas, one rural and one urban, defined by postcodes. The numbers of consumers in these areas were similar and they were served by similar numbers of general practitioners. The number of defined daily doses (DDDs) of celecoxib and rofecoxib dispensed at specific times was calculated.

Results

Statistical analysis revealed no significant difference between the total numbers of DDDs of COX-2-selective non-steroidal anti-inflammatory drugs dispensed in the rural and urban groups over the period August 2000 to December 2002 (P=0.81). The rate of uptake of usage was also clearly similar between the urban and the rural groups. Total usage peaked in August 2000 in both groups (urban 39 DDD/1,000 people per day; rural 37 DDD/1,000 people per day), coinciding with the pharmaceutical benefits scheme (subsidized) listing of celecoxib. The number of DDDs declined dramatically in the following month, and then peaked again in May 2002 (urban 34, rural 36). The number of DDDs then steadily decreased in both areas after October 2002.

Conclusion

The results suggest that the marketing of the new COX-2 inhibitors and the patients’ anticipation of a safe and effective treatment have overcome the geographical boundaries of Queensland. Both areas had very high rates of uptake of the prescribing of these new drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Access Economics (2001) The prevalence, cost and disease burden of arthritis in Australia. Prepared for the Arthritis Foundation of Australia, Access Economics, Canberra, March 2001. http://www.accesseconomics.com.au. Cited 5 October 2003

  2. Gomez Cerezo J, Lubomirov Hristov R, Carcas Sansuan AJ, Vazquez Rodriguez JJ (2003) Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharmacol 59(2):169–175

    PubMed  Google Scholar 

  3. Kerr SJ, Mant A, Horn FE, McGeechan K, Sayer GP (2003) Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 179(8):403–407

    Google Scholar 

  4. Cutts C, Tett SE (2003) Doctors perceptions of the influences on their prescribing: a comparison of general practitioners based in rural and urban Australia. Eur J Clin Pharmacol 58(11):761–766

    Google Scholar 

  5. Australian Bureau of Statistics: AusStats. http://www.library.uq.edu.au/. Cited 10 February 2003

  6. Health Wiz Version 4.0. National Social Health Statistical Database. Commonwealth Department of Health and Family Services. http://www.library.uq.edu.au./. Cited 10 February 2003

  7. Mant A, Eyland A (1986) General practice location and the use of hypnotics by the elderly. Med J Aust 144:390

    Google Scholar 

  8. Cutts C, Tett SE (2003) Influence on doctor’s prescribing: is geographical remoteness a factor? Aust J Rural Health 11:124–130

    Article  Google Scholar 

  9. Coleman JS, Katz E, Menzel H (1966) Medical innovation—a diffusion study. Bobbs-Merrill, New York

    Google Scholar 

  10. Steffensen FH, Sorensen HT, Olesen F (1999) Diffusion of new drugs in Danish general practice. Fam Prac 16:407–413

    Article  CAS  PubMed  Google Scholar 

  11. Prosser H, Almond S, Walley T (2003) Influences on GPs’ decisions to prescribe new drugs-the importance of who says what. Fam Prac 20:61–68

    Article  Google Scholar 

  12. Jones MI, Greenfield SM, Bradley CP (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 323:1–7

    Article  Google Scholar 

  13. Brodie M, Levitt L (2002) Drug advertising: the right or wrong prescription for our ailments? Nat Rev Drug Discov 1(11):916–920

    Article  Google Scholar 

  14. Moynihan R (2003) Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1. Entanglement. BMJ 326:1189–1192

    Article  Google Scholar 

  15. Moynihan R, Bero L, Ross-Degnan D, Henry D, Lee K, Watkins J, Mah C, Soumerai SB (2000) Coverage by the news media of the benefits and risks of medications. New Engl J Med 342(22):1645–1650

    Article  Google Scholar 

  16. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM (1993) Primary non-compliance with prescribed medication in primary care. BMJ 307(6908):846–848

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Queensland, Brisbane, QLD, 4072, Australia

    K. Behan, C. Cutts & Susan E. Tett

  2. Queensland Rural Medical Support Agency, Alderley, QLD, Australia

    K. Behan & C. Cutts

  3. St Helens Primary Care Trust, St Helens, Merseyside, UK

    C. Cutts

Authors
  1. K. Behan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Cutts
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan E. Tett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan E. Tett.

Additional information

The authors had no financial or other support, or financial or professional relationships that may pose a competing interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behan, K., Cutts, C. & Tett, S.E. Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. Eur J Clin Pharmacol 61, 55–58 (2005). https://doi.org/10.1007/s00228-004-0865-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0865-6

Keywords

Search

Navigation